{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:42:05Z","timestamp":1765953725451,"version":"3.48.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Febrile infection-related epilepsy syndrome (FIRES) is a catastrophic, drug-resistant epileptic encephalopathy characterized by acute onset following febrile illness and progression to (super-)refractory status epilepticus. We report a case of FIRES in a previously healthy 5-year-and-11-month-old boy who developed super-refractory status epilepticus (SRSE) on day 6 of a nonspecific febrile illness. The seizures were characterized by upward eye deviation, generalized tonic posturing, perioral cyanosis, and persistent impairment of consciousness. Despite comprehensive treatments including multiple immunotherapies (intravenous immunoglobulin administration, methylprednisolone pulse therapy, tocilizumab, and anakinra), ketogenic diet, multiple anti-seizure medications, and management of complications (intracranial pressure control, anti-infective therapy, and respiratory support), seizures remained refractory. Due to refractory seizures, intravenous lidocaine (3\u2005mg\/kg\/h) was initiated after failed trials of midazolam, propofol and chloral hydrate, and only partial response to ketamine. With a consecutive 35-day infusion (cumulative duration &amp;gt;45 days), this regimen produced substantial reductions in both seizure frequency and severity, with clinically significant improvement in seizure control. Electroencephalogram (EEG) monitoring showed a decrease in the frequency and intensity of epileptic discharges, and improved background activity. The patient's level of consciousness also showed signs of improvement. This case is notable as few reports exist on the use of lidocaine in FIRES patients. It highlights the potential of lidocaine as a valuable anti-seizure option in FIRES management, suggesting the need for further investigation into its safety, efficacy, optimal dosage, and treatment duration in a larger cohort of FIRES patients.<\/jats:p>","DOI":"10.3389\/fped.2025.1696294","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:37:21Z","timestamp":1765953441000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Lidocaine as a potential anti-seizure therapy for pediatric FIRES: a promising therapeutic approach"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xifang","family":"Ru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/epi.14016","article-title":"Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions","volume":"59","author":"Hirsch","year":"2018","journal-title":"Epilepsia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/NDT.S177803","article-title":"Febrile infection-related epilepsy syndrome (FIRES): prevalence, impact and management strategies","volume":"15","author":"Serino","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/j.1469-8749.2012.04435.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES) is not caused by SCN1A, POLG, PCDH19 mutations or rare copy number variations","volume":"54","author":"Appenzeller","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/dmcn.14553","article-title":"New-onset refractory status epilepticus and febrile infection-related epilepsy syndrome","volume":"62","author":"Specchio","year":"2020","journal-title":"Dev Med Child Neurol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/epi.14022","article-title":"New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives","volume":"59","author":"Gaspard","year":"2018","journal-title":"Epilepsia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106454","DOI":"10.1016\/j.eplepsyres.2020.106454","article-title":"Ketogenic diet and neuroinflammation","volume":"167","author":"Koh","year":"2020","journal-title":"Epilepsy Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1111\/epi.17391","article-title":"International consensus recommendations for management of new onset refractory status epilepticus (NORSE) including febrile infection-related epilepsy syndrome (FIRES): summary and clinical tools","volume":"63","author":"Wickstr\u00f6m","year":"2022","journal-title":"Epilepsia"},{"key":"B8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1017\/cjn.2015.278","article-title":"Lidocaine for status epilepticus in pediatrics","volume":"42","author":"Zeiler","year":"2015","journal-title":"Can J Neurol Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.bja.2019.06.014","article-title":"Molecular mechanisms of action of systemic lidocaine in acute and chronic pain: a narrative review","volume":"123","author":"Hermanns","year":"2019","journal-title":"Br J Anaesth"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1111\/epi.17591","article-title":"Treatment of new onset refractory status epilepticus\/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult","volume":"64","author":"Girardin","year":"2023","journal-title":"Epilepsia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/j.1528-1167.2011.03250.x","article-title":"Febrile infection-related epilepsy syndrome (FIRES): pathogenesis, treatment, and outcome: a multicenter study on 77 children","volume":"52","author":"Kramer","year":"2011","journal-title":"Epilepsia"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/epi.17933","article-title":"Second-line immunotherapy in new onset refractory status epilepticus","volume":"65","author":"Hanin","year":"2024","journal-title":"Epilepsia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1055\/s-0034-1389898","article-title":"Lidocaine treatment in refractory status epilepticus resulting from febrile infection-related epilepsy syndrome: a case report and follow-up","volume":"46","author":"Capizzi","year":"2015","journal-title":"Neuropediatrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1468-2982.2008.01800.x","article-title":"Neuropsychiatric side-effects of lidocaine: examples from the treatment of headache and a review","volume":"29","author":"Gil-Gouveia","year":"2009","journal-title":"Cephalalgia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/dsu.12064","article-title":"Serum lidocaine levels and cutaneous side effects after application of 23% lidocaine 7% tetracaine ointment to the face","volume":"39","author":"McCleskey","year":"2013","journal-title":"Dermatol Surg"},{"key":"B16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/medicina57080782","article-title":"Lidocaine: a local anesthetic, its adverse effects and management","volume":"57","author":"Bahar","year":"2021","journal-title":"Medicina (Kaunas)"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1696294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:37:23Z","timestamp":1765953443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1696294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":16,"alternative-id":["10.3389\/fped.2025.1696294"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1696294","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1696294"}}